Clincosm LogoSign in Get a demo

refractory

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Refractory, Recurrence, Hemophagocytic Lymphohistiocytosis Trial (GTP regimen)

Not yet recruiting
  • Refractory
  • +2 more
  • GTP regimen
  • (no location specified)
Sep 8, 2023

Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Chapel Hill, North Carolina
  • +2 more
Jun 9, 2023

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-219)

Recruiting
  • Acute Myeloid Leukemia
  • +12 more
  • Los Angeles, California
  • +6 more
Jun 1, 2022

Acute Lymphoblastic Leukemia, CD19 Positive, Relapse Trial in Suzhou (Humanized CD19 CAR-T cells, Humanized CD19 CAR-T cells

Recruiting
  • Acute Lymphoblastic Leukemia
  • +3 more
  • Humanized CD19 CAR-T cells
  • Humanized CD19 CAR-T cells with CRS suppression technology
  • Suzhou, Jiangsu, China
    The first affiliated hospital of soochow university
May 18, 2022

Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory Trial in New York (EGFRt/19-28z/4-1BBL CAR T cells)

Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +2 more
  • EGFRt/19-28z/4-1BBL CAR T cells
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Apr 1, 2022

AML, Recurrent, Refractory Trial in Jinan (Allogeneic NK cell regimen group)

Not yet recruiting
  • AML
  • +3 more
  • Allogeneic NK cell regimen group
  • Jinan, Shandong, China
    The 2nd Hospital of Shandong University
Oct 21, 2020

Refractory, Relapsed, B Cell Lymphoma Trial in Zhengzhou (CAR-T cells)

Unknown status
  • Refractory
  • +3 more
  • CAR-T cells
  • Zhengzhou, Henan, China
  • +1 more
Mar 19, 2019

B-Cell Lymphoma Stage I, Refractory, Relapsed Trial in Zhengzhou (CD19/CD20 bispecific CAR-T cells)

Unknown status
  • B-Cell Lymphoma Stage I
  • +2 more
  • CD19/CD20 bispecific CAR-T cells
  • Zhengzhou, Henan, China
  • +1 more
Mar 19, 2019

Hodgkin Lymphoma, Refractory, Relapse Trial in Worldwide (DHAP, Brentuximab Vedotin, Autologous Peripheral Blood Stem Cell

Unknown status
  • Hodgkin Lymphoma
  • +2 more
  • Copenhagen, Denmark
  • +12 more
Mar 12, 2018

Sinusitis, Chronic Disease, Refractory Trial in Marseille (Biological sample)

Unknown status
  • Sinusitis
  • +2 more
  • Biological sample
  • Marseille, France
    Service ORL et de Chirurgie Cervico - Faciale/ AP-HM
Mar 30, 2015

Refractory, Multiple Myeloma, Relapse Trial (bortezomib)

Completed
  • Refractory
  • +2 more
  • (no location specified)
May 16, 2011